New Zealand markets close in 6 hours 2 minutes

ImmunoPrecise Antibodies Ltd. (IPA)

NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
6.240.00 (0.00%)
At close: 3:59PM EDT

ImmunoPrecise Antibodies Ltd.

3204–4464 Markham Street
Victoria, BC V8Z 7X8
Canada

http://www.immunoprecise.com

Sector(s)Healthcare
IndustryBiotechnology
Full-time employees73

Key executives

NameTitlePayExercisedYear born
Dr. Jennifer Lynne Bath Ph.D.CEO, Pres & Director852.87kN/AN/A
Ms. Lisa HelblingChief Financial Officer354.42kN/AN/A
Dr. Stefan LangChief Bus. Officer177.5kN/AN/A
Mr. David E. OrtonChief Operating OfficerN/AN/AN/A
Dr. Ilse RoodinkChief Scientific OfficerN/AN/AN/A
Ms. Carla DahlVP of MarketingN/AN/AN/A
Dr. Barry Neil DuplantisVP of Client RelationsN/AN/AN/A
Amounts are as of 31 December 2020, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

ImmunoPrecise Antibodies Ltd., together with its subsidiaries, engages in antibody production and related services in the United States, Canada, Europe, and internationally. The company offers a range of antibodies, enzymes, enzyme activity assays, arthritis animal products, proteins, deiminated proteins, organoid growth factors, and hybridoma products for research purposes. Its services include custom antigen modeling, design, and manufacturing; B cell sorting, screening, and sequencing; custom, immune, and naive phage display production and screening; transgenic animals and multi-species antibody discovery; bi-specific, tri-specific, VHH, and VNAR (shark) antibody manufacturing; DNA cloning, protein and antibody downstream processing; antibody characterization on label-free biosensors and antibody engineering; transient and stable cell line generation; antibody optimization and humanization; hybridoma production with multiplexed, high-throughput screening, and clone-picking; and cryopreservation. The company has a research collaboration agreement with Pierre Fabre S.A for antibody discovery. ImmunoPrecise Antibodies Ltd. was incorporated in 1983 and is based in Victoria, Canada.

Corporate governance

ImmunoPrecise Antibodies Ltd.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.